Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine
and melphalan together with antithymocyte globulin before a peripheral blood stem cell
transplant works in treating patients with autoimmune neurologic disease that did not respond
to previous therapy. In autoimmune neurological diseases, the patient's own immune system
'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral
nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine,
melphalan, and antithymocyte globulin, before a peripheral blood stem cell transplant weakens
the immune system and may help stop the immune system from 'attacking' a patient's nervous
system. When the patient's own (autologous) stem cells are infused into the patient they help
the bone marrow make red blood cells, white blood cells, and platelets so the blood counts
can improve.